Literature DB >> 32111799

Comparative Analysis of Immunoinflammatory and Nutritional Measures in Surgically Resected Esophageal Cancer: A Single-center Retrospective Study.

Makoto Sakai1, Makoto Sohda2, Hideyuki Saito1, Yasunari Ubukata1, Nobuhiro Nakazawa1, Kengo Kuriyama1, Keigo Hara1, Akihiko Sano1, Kyoichi Ogata1, Takehiko Yokobori3, Ken Shirabe4, Hiroshi Saeki1.   

Abstract

BACKGROUND/AIM: Several immunoinflammatory and nutritional measures have been reported to be good prognostic indicators for esophageal cancer (EC). However, the association between those markers and the postoperative survival of EC patients remains unclear due to varying study designs and treatment strategies. The aim of this study was to compare the significance of preoperative immunoinflammatory and nutritional measures in patients with EC. PATIENTS AND METHODS: One hundred and five patients with EC who underwent McKeown esophagectomy with gastric tube reconstruction without neoadjuvant therapy between 2006 and 2014 were included in this study. The prognostic values of preoperative modified Glasgow prognostic score (mGPS), controlling nutritional status (CONUT) score, prognostic nutritional index (PNI), C-reactive protein (CRP)-to-albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were investigated using univariate and multivariate survival analyses.
RESULTS: Multivariate analysis revealed that CAR and pathological stage are independent prognostic factors for overall survival (OS). CAR was significantly associated with more advanced pathological stage as both a subject and a continuous variable.
CONCLUSION: Preoperative CAR was an independent prognostic factor for the OS of EC patients who underwent McKeown esophagectomy. The tumor-stage related increase in CAR demonstrated that a high CAR is associated with tumor progression in EC patients. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  C-reactive protein; Esophageal Neoplasms; albumin; inflammation; nutrition

Mesh:

Substances:

Year:  2020        PMID: 32111799      PMCID: PMC7157860          DOI: 10.21873/invivo.11853

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  22 in total

1.  The seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals: the new era of data-driven revisions.

Authors:  Valerie W Rusch; Thomas W Rice; John Crowley; Eugene H Blackstone; Ramon Rami-Porta; Peter Goldstraw
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04       Impact factor: 5.209

2.  Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma.

Authors:  Masaki Kunizaki; Tetsuro Tominaga; Kouki Wakata; Takuro Miyazaki; Keitaro Matsumoto; Yorihisa Sumida; Shigekazu Hidaka; Takuya Yamasaki; Toru Yasutake; Terumitu Sawai; Ryuji Hamamoto; Atsushi Nanashima; Takeshi Nagayasu
Journal:  Mol Clin Oncol       Date:  2017-12-08

3.  Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma.

Authors:  Norifumi Harimoto; Tomoharu Yoshizumi; Kazuhito Sakata; Akihisa Nagatsu; Takashi Motomura; Shinji Itoh; Noboru Harada; Toru Ikegami; Hideaki Uchiyama; Yuji Soejima; Yoshihiko Maehara
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

4.  Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer.

Authors:  Yasunori Otowa; Tetsu Nakamura; Gosuke Takiguchi; Ayako Tomono; Masashi Yamamoto; Shingo Kanaji; Tatsuya Imanishi; Satoshi Suzuki; Kenichi Tanaka; Tomoo Itoh; Yoshihiro Kakeji
Journal:  Dis Esophagus       Date:  2014-12-17       Impact factor: 3.429

5.  Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada; Yoshihiro Nabeya; Shin-Ichi Okazumi; Hisahiro Matsubara; Tooru Shiratori; Taito Aoki; Makoto Sugaya; Yukimasa Miyazawa; Hideki Hayashi; Shin-Ichi Miyazaki; Takenori Ochiai
Journal:  J Surg Oncol       Date:  2003-08       Impact factor: 3.454

Review 6.  C-reactive protein and malignancy: clinico-pathological association and therapeutic implication.

Authors:  Chia-Siu Wang; Chien-Feng Sun
Journal:  Chang Gung Med J       Date:  2009 Sep-Oct

7.  Prognostic Value of Preoperative Systemic Immunoinflammatory Measures in Patients with Esophageal Cancer.

Authors:  Yusuke Ishibashi; Hironori Tsujimoto; Shuichi Hiraki; Isao Kumano; Yoshihisa Yaguchi; Hiroyuki Horiguchi; Shinsuke Nomura; Nozomi Ito; Eiji Shinto; Suefumi Aosasa; Junji Yamamoto; Hideki Ueno
Journal:  Ann Surg Oncol       Date:  2018-07-17       Impact factor: 5.344

8.  Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer.

Authors:  Tsutomu Namikawa; Eri Munekage; Masaya Munekage; Hiromichi Maeda; Tomoaki Yatabe; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Oncology       Date:  2016-05-26       Impact factor: 2.935

9.  Association between the inflammatory biomarker, C-reactive protein, and the response to radiochemotherapy in patients with esophageal cancer.

Authors:  Harun Badakhshi; David Kaul; Kuai-LE Zhao
Journal:  Mol Clin Oncol       Date:  2016-01-28

10.  Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer.

Authors:  Xuechao Liu; Xiaowei Sun; Jianjun Liu; Pengfei Kong; Shangxiang Chen; Youqing Zhan; Dazhi Xu
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

View more
  6 in total

1.  Preoperative C-Reactive Protein/Albumin Ratio as a Predictive Factor for Gallbladder Carcinoma.

Authors:  Masashi Utsumi; Hideki Aoki; Seichi Nagahisa; Seitaro Nishimura; Yuta Une; Yuji Kimura; Megumi Watanabe; Fumitaka Taniguchi; Takashi Arata; Koh Katsuda; Kohji Tanakaya
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Impact of the Ratio of Visceral Fat Area (VFA) to Psoas Muscle Area (PMA) (V/P Ratio) on Survival for Surgically Resected Esophageal Cancer.

Authors:  Makoto Sakai; Makoto Sohda; Shintaro Uchida; Arisa Yamaguchi; Takayoshi Watanabe; Hideyuki Saito; Yasunari Ubukata; Nobuhiro Nakazawa; Kengo Kuriyama; Akihiko Sano; Hiroomi Ogawa; Takehiko Yokobori; Ken Shirabe; Hiroshi Saeki
Journal:  Ann Surg Oncol       Date:  2022-03-08       Impact factor: 5.344

3.  Albumin-Derived NLR Score is a Novel Prognostic Marker for Esophageal Squamous Cell Carcinoma.

Authors:  Tomoki Abe; Taro Oshikiri; Hironobu Goto; Takashi Kato; Manabu Horikawa; Ryuichiro Sawada; Hitoshi Harada; Naoki Urakawa; Hiroshi Hasegawa; Shingo Kanaji; Kimihiro Yamashita; Takeru Matsuda; Yoshihiro Kakeji
Journal:  Ann Surg Oncol       Date:  2021-11-22       Impact factor: 5.344

4.  Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score.

Authors:  Liwei Zhao; Ji Sun; Kai Wang; Shengcheng Tai; Runmiao Hua; Yufu Yu; Yi Fan; Jiaguo Huang
Journal:  Cancer Manag Res       Date:  2021-08-16       Impact factor: 3.989

5.  Low Preoperative Albumin-to-Globulin Ratio Is a Marker of Poor Prognosis in Patients With Esophageal Cancer.

Authors:  Yosuke Atsumi; Shinnosuke Kawahara; Sho Kakuta; Atsushi Onodera; Kentaro Hara; Keisuke Kazama; Masakatsu Numata; Toru Aoyama; Ayako Tamagawa; Hiroshi Tamagawa; Takashi Oshima; Norio Yukawa; Yasushi Rino
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 6.  Clinlabomics: leveraging clinical laboratory data by data mining strategies.

Authors:  Xiaoxia Wen; Ping Leng; Jiasi Wang; Guishu Yang; Ruiling Zu; Xiaojiong Jia; Kaijiong Zhang; Birga Anteneh Mengesha; Jian Huang; Dongsheng Wang; Huaichao Luo
Journal:  BMC Bioinformatics       Date:  2022-09-24       Impact factor: 3.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.